Randomized double-blind clinical trial of Moluodan (摩罗丹) for the treatment of chronic atrophic gastritis with dysplasia

Chinese Journal of Integrative Medicine

Volumn 22, Issue 1, 2016, Pages 9-18

  Tang, Xu dong ^a   Zhou, Li ya ^b   Zhang, Shu tian ^c   Xu, You qing ^d   Cui, Quan cai ^e   Li, Li ^f   Lu, Jing jing ^b   Li, Peng ^c   Lu, Fang ^a   Wang, Feng yun ^a   Wang, Ping ^a   Bian, Li qun ^a   Bian, Zhao xiang ^g  

^a XIYUAN HOSPITAL   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^g HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

chronic atrophic gastritis; folic acid; gastric epithelial dysplasia; Moluodan; randomized clinical trial

Indexed keywords

CHINESE DRUG; DIGESTIVE TRACT AGENT; FOLIC ACID; MOLUODAN; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ADULT; ARTICLE; ATROPHIC GASTRITIS; BIOPSY; CHRONIC DISEASE; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DYSPLASIA; EPIGASTRIC PAIN; ERUCTATION; ERYTHEMA; FEMALE; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; DRUG EFFECTS; GASTRITIS, ATROPHIC; HELICOBACTER PYLORI; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY;

CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; GASTRITIS, ATROPHIC; GASTROSCOPY; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84953355572     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-015-2114-5     Document Type: Article

References (33)

1. Lewin KJ. Nomenclature problems of gastrointestinal epithelial neoplasia. Am J Surg Pathol 1998;22:1043–1047.
2. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.
3. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut 1999;45:784–790.
4. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 1985;12:2–10.
5. Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998;1:31–50.
6. Wu B. The outcome of low-grade gastric intraepithelial neoplasia and the comparative study between endoscopic therapy and surgical resection for high-grade gastric intraepithelial neoplasia and early gastric cancer [dissertation]. Beijing: Chinese PLA Postgraduate Medical School; 2011.
7. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002;51:130–131.
8. Li EF, Mei JQ, Su TC, Miu YX. Regulating function of Moluodan on the gastric electrogram of chronic gastric diseases. Chin Tradit Patent Med (Chin) 1992;14:24–25.
9. Jin ZH, Kang Y, Jiao JJ, Ma DL, Zhang CL. A experimental study on the effect of Moluodan on secretion function in mice with chronic gastritis. Tianjin Med (Chin) 1990;3:179–180.
10. Jiao JJ, Ma DL, Kang Y, Jin ZH, Zhang CL. The pathological changes of experimental mice with chronic gastritis treated by Moluodan. Tianjin Tradit Chin Med (Chin) 1990;3:38–39.
11. Yu Z, Wang G, Chen GY, Chang J, Zhang Y, Zhang RM. Muoluodan concentrated pill in treatment of chronic atrophic gastritis (the stomach-yin of deficiency and stagnated blood of stomach meridian): a prospective, randomized, controlled trial. West China Med J (Chin) 2007;22:287–289.
12. Guo XJ. The curative effect observation on 200 cases of intetinal metaplasia of atrophic gastritis treated with Moluo Pills. J Beijing Univ Tradit Chin Med (Chin) 1997;17:33–35.
13. Si JM, Sun LM, Fan YJ, Wang LJ. Trial of a novel endoscopic tattooing biopsy forceps on animal model. World J Gastroenterol 2005;11:1859–1861.
14. Digestive Disease Branch of Chinese Medical Association. Consensus on chronic gastritis in China (Shanghai 2006). Chin J Gastroenterol (Chin) 2007;27:45–49.
15. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251–255.
16. Wang F. Weifuchun for the treatment of 40 cases with chronic atrophic gastritis. Fujian Tradit Chin Med (Chin) 2003;34:31.
17. Wu HM. Clinical research on Weifuchun for the treatment of chronic atrophic gastritis. Chin Med Factory Mine (Chin) 2000;13:215–216.
18. Zhu SS, Joel Mason, Shi Y, Hu YB, Li RR, Wang M, et al. The interventional effect of folic acid on the development of gastric and other gastrointestinal cancers—clinical trial and follow-up for seven years. Chin J Gastrocnterol (Chin) 2002;7:73–78.
19. Xiao SD, Meng XJ, Shi Y, Hu YB, Zhu SS, Wang CW. Interventional study of high dose folic acid in gastric carcinogenesis in beagles. Gut 2002;50:61–64.
20. Zhu SS, Hu YB, Shi Y, Fang JY, Gu WQ, Jiang SJ, et al. Reversion of the precancerous lesions of gastric cancer with some vitamins: a preliminary clinical observasion. Chin J Gastroenterol (Chin) 1996;1:70–74.
21. Chinese Medical Association of Digestive Endoscopy. Endoscopic classification and trial standards on treatment of chronic gastritis. Chin J Dig Endosc (Chin) 2004;21:77–78.
22. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.
23. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881–1888.
24. Tang XD, Wang P, Liu BY, Zi MJ. Development and analysis of patient reported outcome instrument for chronic gastrointestinal disease. J Tradit Chin Med (Chin) 2009;50:27–29.
25. Wang P, Tang XD, Liu BY, Zi MJ. Development of a patientreported outcome instrument for chronic gastrointestinal diseases: item selection. J Chin Intergr Med (Chin) 2012;10:1092–1098.
26. Sun LM, Si JM, Chen SJ, Liu WL, Zhao L, Wang LJ. The establishment and clinical applicance of technique of mucosa marking targeting biopsy. Heptogastroenterology 2009;56:59–62.
27. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. World Health Organization. IARC Monogr Eval Carcinog Risks Hum 1997;61:177.
28. Hu YP, Cui L, Yang JJ, Liu T, Wang XF, Liu FG. Diagnosis and clinical significance of gastric tunica mucosa epithelial reactive hyperplasia and dysplasia. Clin Misdiagnosis Mistherapy (Chin) 2012; 25:65–68.
29. Dong B, Xie YQ, Chen K, Wang T, Tang W, You WC, et al. Differences in biological features of gastric dysplasia, indefinite dysplasia, reactive hyperplasia and discriminant analysis of these lesions. World J Gastroenterol 2005;11:3595–600.
30. Li P, Zhang ST. Criteria of endoscopic diagnosis of chronic gastritis and Its appraisal. Chin J Clin Gastroenterol (Chin) 2006;18:136–138.
31. Yang XY, Wu YL, Zhu YH, Tang ZP, Zhu SL, Feng L, et al. Gastric mucosal low-grade intraepithelial neoplasia treated with Weifuchun combined with folic acid and its outcome. J Intern Med Concepts Pract (Chin) 2013;8:24–28.
32. Yuan WQ, Wang L, Wang XH. Research progress on clinical pathology of gastric intraepithelial neoplasia. Chin J Coal Industry Med (Chin) 2004;7:490–491.
33. Xu CP, Liu WW. Follow-up study on chronic gastritis, intestinal metaplasia and dysplasia. Chin J Dig (Chin) 1984:10.